Health and Fitness Health and Fitness
Tue, March 5, 2013
Mon, March 4, 2013
Sun, March 3, 2013
Sat, March 2, 2013
Fri, March 1, 2013
Thu, February 28, 2013
Wed, February 27, 2013
Tue, February 26, 2013
Mon, February 25, 2013
Sun, February 24, 2013
Sat, February 23, 2013
Fri, February 22, 2013
Thu, February 21, 2013
[ Thu, Feb 21st 2013 ] - Market Wire
Inorganic Growth of Healthcare
Wed, February 20, 2013
Tue, February 19, 2013
Mon, February 18, 2013
Sun, February 17, 2013
Fri, February 15, 2013
Thu, February 14, 2013
Wed, February 13, 2013
Tue, February 12, 2013
Mon, February 11, 2013

DiaMedica Announces Resignation of Board Member


//health-fitness.news-articles.net/content/2013/ .. edica-announces-resignation-of-board-member.html
Published in Health and Fitness on Friday, February 22nd 2013 at 15:45 GMT by Market Wire   Print publication without navigation


February 22, 2013 18:35 ET

DiaMedica Announces Resignation of Board Member

MINNEAPOLIS, MINNESOTA--(Marketwire - Feb. 22, 2013) - DiaMedica (TSX VENTURE:DMA) announces today that David Allan has resigned from the Company's board of directors, effective February 22, 2013.

"On behalf of our board of directors, I thank David for his valuable service and contributions and wish him well in future endeavors," stated Rick Pauls, Chairman & CEO of DiaMedica.

About DiaMedica

DiaMedica Inc. (TSX VENTURE:DMA) is a biotechnology company developing first-in-class treatments for the treatment of diabetes. DiaMedica's lead compound, DM-199, is a recombinant human protein for the treatment of both Type 1 and Type 2 diabetes and their complications. The Company is also developing the first therapeutic GPCR agonist monoclonal antibody, DM-204, for the treatment of Type 2 diabetes and cardiovascular disease. DiaMedica's shares trade on the Toronto Stock Exchange Venture (TSX VENTURE:DMA). For more information please visit [ www.diamedica.com ].

FORWARD-LOOKING STATEMENTS

The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.




Publication Contributing Sources